Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Contingent Liabilities and Commitments (Details Textual)

v3.19.1
Contingent Liabilities and Commitments (Details Textual) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Dec. 18, 2017
Aug. 31, 2017
Oct. 31, 2016
Mar. 31, 2015
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Aug. 06, 2018
Statement Line Items [Line Items]                
Company accrued in other accounts payable         $ 425      
Motor lease expenses         56 $ 58    
Payment of award expenses $ 14              
Personal damages         20      
Damages claims         $ 33      
Distribution and supply agreement, description         The Company is entitled to €1,500 upon execution of the agreement plus milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) €300 upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and €300 upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between €750 and €1,600 following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between €300 and up to €4,025 upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson. On January 25, 2018 the Company received a first payment of approximately USD 2,200 from Gebro and in August 2018 received the approximately USD 350 upon reaching the first milstone.      
Lease payments per month         $ 5      
Lease term         The lease is for a period ending April 2021.      
Additional milestone payment               $ 2,000
Cipher [Member]                
Statement Line Items [Line Items]                
Upfront payments       $ 1,292        
Royalty payments, percentage       16.50%        
CKD [Member]                
Statement Line Items [Line Items]                
Upfront payments   $ 500         $ 500  
Upfront payments, additional     $ 2,500          
Royalty payments, percentage     23.00%          
Euro [Member]                
Statement Line Items [Line Items]                
Concession commission         $ 25      
Annual royalties         10      
Total royalties         $ 850      
Patent agreement, description         The patent under the agreement, as follows: (i) € 50 upon initiation of Phase I studies; (ii) € 100 upon initiation of Phase II studies; (iii) € 200 upon initiation of Phase III studies; and (iv) € 500 upon marketing approval by any regulatory authority.      
Royalty payments, percentage         10.00%      
CAD [Member] | Cipher [Member]                
Statement Line Items [Line Items]                
Upfront payments       $ 1,650        
Upfront payments, additional       $ 2,000        
NIS [Member]                
Statement Line Items [Line Items]                
Payment of award expenses $ 50              
Personal damages         $ 73      
Damages claims         $ 125      
Top of range [Member]                
Statement Line Items [Line Items]                
Percentage of net sales         3.00%      
Bottom of range [Member]                
Statement Line Items [Line Items]                
Percentage of net sales         2.00%